Moffitt Cancer Center | Strategic Alliance Partners

July 14, 2023

Experts Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, reflect on recent updates to the treatment guidelines for patients with follicular lymphoma.

July 10, 2023

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

July 10, 2023

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

July 06, 2023

George Simon, MD, FACP, FCCP, discusses findings from an FDA pooled analysis of PD-1/PD-L1 inhibitors with or without chemotherapy in patients with non–small cell lung cancer.

July 05, 2023

Andrew S. Brohl, MD, discusses the safety and immunologic responses with intratumoral administration of Idx-Hu2.0 in patients with advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.

July 05, 2023

Danielle K. DePalo, MD, discusses findings from a study comparing first-line isolated limb infusion/perfusion vs immune checkpoint inhibitors and intratumoral therapy in patients with surgically unresectable melanoma in-transit metastases.

July 05, 2023

A treatment regimen consisting of pepinemab plus trastuzumab and a dendritic cell vaccine, followed by autologous CD4-positive T cells, is under investigation in a phase 1 trial in patients with metastatic HER2-positive breast cancer.

July 03, 2023

A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

July 03, 2023

Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.

June 30, 2023

Andreas Saltos, MD, discusses final results from a phase 2 trial of first-line pembrolizumab plus vorinostat in patients with metastatic non–small cell lung cancer.

June 29, 2023

Bruna Pellini, MD, discusses the use of circulating tumor DNA monitoring to inform maintenance outcomes in patients with advanced non–small cell lung cancer treated with induction therapy with atezolizumab, carboplatin, and nab-paclitaxel.

June 27, 2023

Damon R. Reed, MD, discusses a phase 2 study of fam-trastuzumab deruxtecan-nxki in adolescent and young adult patients with recurrent HER2-positive osteosarcoma.

June 26, 2023

Rami Komrokji, MD, discusses key findings from an expanded analysis of the classification of patients with myelodysplastic syndromes.

June 26, 2023

Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

June 26, 2023

Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

June 21, 2023

Rami Komrokji, MD, discusses ongoing clinical trials in patients with higher- and lower-risk myelodysplastic syndromes.

June 19, 2023

Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.

June 19, 2023

Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.

June 10, 2023

Timothy I Shaw, PhD, discusses the genetic heterogeneity between paired primary and metastatic solid tumors, as well as the implications for neoantigen-based personalized vaccines in cancer care.

June 07, 2023

The combination of dabrafenib and trametinib plus navitoclax generated responses and met the co-primary end point for complete response rate vs historical controls in patients with BRAF V600–mutant metastatic melanoma.